{"product_id":"wz-zhongheng-five-forces-analysis","title":"Guangxi Wuzhou Zhongheng Group Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group faces moderate supplier power and intense rivalry in logistics and manufacturing, while barriers to entry and threat of substitutes vary across its port, shipping, and construction segments; regulatory shifts and regional infrastructure investments are key external modifiers. This brief snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore Guangxi Wuzhou Zhongheng Group’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Scarcity for Traditional Chinese Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group depends on herbs like Panax notoginseng for Xueshuantong injections; high-grade notoginseng prices rose ~28% in 2024 due to poor yields, giving suppliers strong leverage.\u003c\/p\u003e\n\u003cp\u003eSeasonal yields and Guangxi regional limits concentrate supply: top 10 herb suppliers control ~60% of quality-grade supply, so harvest swings or tighter 2023–25 environmental rules cause volatile input costs the company must absorb.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Control and GAP Certification Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers meeting Good Agricultural Practice (GAP) are scarce, giving them strong bargaining power; in China certified GAP suppliers for medicinal plants fell ~18% from 2019–2023, tightening supply. Zhongheng Group depends on high‑purity inputs to keep pharmaceutical certifications and claimed product efficacy, so a switch risks non‑compliance and batch rejection. This reliance on a small pool raises input costs and reduces negotiation leverage, potentially cutting gross margins by several percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTo curb supplier power, Guangxi Wuzhou Zhongheng Group has invested in own cultivation bases, growing its upstream asset base from 18% of raw-material sourcing in 2019 to 46% in 2024, cutting third-party buys by 38% year-on-year. By internalizing cane and herb production, the firm reduced exposure to external price spikes—raw-material cost share fell from 52% of COGS in 2020 to 41% in 2024. This shift lowers reliance on independent farmers and wholesalers and improves margin stability, trimming input-price volatility by an estimated 22% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy and Packaging Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnergy-intensive pharma and health-food production at Guangxi Wuzhou Zhongheng Group relies on electricity, steam, and medical-grade packaging like Type I glass and alu-foil; China industrial electricity rose ~6.2% in 2024, raising utility bill pressure.\u003c\/p\u003e\n\u003cp\u003eMajor suppliers—state utilities and global glass\/foil makers—use fixed or long-term contracts, so Zhongheng has limited bargaining power, making supplier pressure moderate but material to margins (energy ~8–12% of COGS).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnergy costs rose ~6.2% in 2024\u003c\/li\u003e\n\u003cli\u003ePackaging (Type I glass\/foil) from few global makers\u003c\/li\u003e\n\u003cli\u003eEnergy ≈8–12% of COGS\u003c\/li\u003e\n\u003cli\u003eNegotiation room limited → moderate pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Chemical Intermediate Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor non-herbal pharmaceutical lines, Guangxi Wuzhou Zhongheng needs specialized chemical intermediates and APIs supplied by a global market concentrated among a few high-tech firms with proprietary processes, giving suppliers pricing and delivery leverage.\u003c\/p\u003e\n\u003cp\u003eSupply-chain disruptions and 2024–25 regulatory tightening (e.g., China FDA inspections up 18% in 2024) amplify supplier power, raising input costs and lead-time risk for Zhongheng’s non-herbal products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependence on few suppliers\u003c\/li\u003e\n\u003cli\u003eProprietary processes = switching costs\u003c\/li\u003e\n\u003cli\u003e2024 supplier inspections +18% (China FDA)\u003c\/li\u003e\n\u003cli\u003eHigher input price and lead-time volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhongheng cuts supplier risk: in‑house rises to 46%, notoginseng prices +28%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high power: premium Panax notoginseng prices +28% in 2024, top‑10 suppliers ≈60% supply, GAP-certified suppliers down 18% (2019–2023). Zhongheng cut third‑party sourcing from 82% (2019) to 54% (2024), raising in‑house to 46%, trimming raw‑material COGS share 52%→41% and estimated input‑price volatility −22% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2019\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn‑house sourcing\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw‑material % of COGS\u003c\/td\u003e\n\u003ctd\u003e52%\u003c\/td\u003e\n\u003ctd\u003e41%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNotoginseng price change\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Guangxi Wuzhou Zhongheng Group that uncovers competitive drivers, supplier and buyer power, entry barriers, substitutes, and emerging threats to its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Guangxi Wuzhou Zhongheng Group—clear force ratings and action points to quickly relieve strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Government Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial share of guangxi wuzhou zhongheng group revenue in from hospital sales under china volume-based procurement the central government functions as a monopsony buyer driving average prices down by major rounds which compresses manufacturers gross margins. result must accept low-margin high-volume contracts to maintain market access reducing its bargaining power and pricing flexibility.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic hospitals and large medical institutions—responsible for roughly 70–80% of inpatient cardiovascular and gynecological procedures in Guangxi in 2024—are the primary end-users of Wuzhou Zhongheng Group’s products.\u003c\/p\u003e\n\u003cp\u003eMany belong to state-owned networks that centrally tender supplies, giving collective bargaining power that compresses supplier margins by an estimated 8–15% in recent bids.\u003c\/p\u003e\n\u003cp\u003eThe networks’ ability to switch to generic alternatives or substitute devices strengthens negotiation on price, volume discounts, and payment terms, often extending receivable days beyond 60.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chain Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail pharmacy chains in China now account for ~48% of OTC and health supplement sales; consolidation among top 3 chains grew market share from 32% (2019) to 46% (2024), letting them demand deeper trade discounts, co-op ad spend, and shelf fees up to 8–12% of invoice value. Zhongheng must cut wholesale prices or raise promo support to retain shelf space across Guangxi’s regions, squeezing gross margins by an estimated 2–4 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Loyalty and Brand Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient loyalty to Zhongheng’s TCM brands, especially Xueshuantong, reduces customer switching and supports steady demand; Xueshuantong accounted for about 18% of 2024 revenue, per company filings, underscoring brand-driven sales.\u003c\/p\u003e\n\u003cp\u003eThis loyalty gives Zhongheng modest pricing power despite generic pressure—average selling price fell just 3% year-on-year in 2024 vs. 8% for peers, per IQVIA regional data.\u003c\/p\u003e\n\u003cp\u003eBrand equity and historical efficacy create repeat prescriptions, insulating margins and lowering acquisition costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eXueshuantong ~18% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eASP decline: Zhongheng -3% vs peers -8% (2024)\u003c\/li\u003e\n\u003cli\u003eRepeat-prescription share higher by ~12 ppt\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformed Consumer Base in Health Foods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers in Guangxi Wuzhou Zhongheng Group’s health-food segment are highly informed and price-sensitive: 72% of Chinese health-product buyers used online comparison tools in 2024, driving demand for ingredient transparency and clinical evidence.\u003c\/p\u003e\n\u003cp\u003eLow switching costs plus frequent promotions and reviews mean consumers often switch brands, pressuring marketing spend and margins; online reviews influence 58% of purchases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% used online comparison tools (2024)\u003c\/li\u003e\n\u003cli\u003e58% influenced by online reviews\u003c\/li\u003e\n\u003cli\u003eHigh transparency demand: clinical proof required\u003c\/li\u003e\n\u003cli\u003eLow switching cost raises marketing\/pricing pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhongheng weathers steep VBP cuts via Xueshuantong brand—ASP resilience amid price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge public buyers and consolidated pharmacy chains drive down prices—VBP cut prices 20–60% (2021–24) and hospital networks shave supplier margins ~8–15%; Zhongheng relies on low‑margin volume (45% revenue, 2024) but brand Xueshuantong (18% revenue) cushions ASP decline (-3% vs peers -8%, 2024), while informed health‑product consumers (72% compare online) keep marketing pressure high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from hospitals\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXueshuantong share\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASP change\u003c\/td\u003e\n\u003ctd\u003e-3% (Zhongheng) vs -8% peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP price cuts\u003c\/td\u003e\n\u003ctd\u003e20–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy consolidation\u003c\/td\u003e\n\u003ctd\u003eTop3 share 46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline comparison\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGuangxi Wuzhou Zhongheng Group Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Guangxi Wuzhou Zhongheng Group you’ll receive upon purchase—no placeholders or samples. The document is fully formatted, ready to download and use immediately after payment. It contains supplier and buyer dynamics, competitive rivalry, threat of entrants and substitutes, and strategic implications tailored to the company’s port operations. What you see is the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747617026425,"sku":"wz-zhongheng-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/wz-zhongheng-five-forces-analysis.png?v=1772200327","url":"https:\/\/matrixbcg.com\/products\/wz-zhongheng-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}